Obesity pill data released by Viking Therapeutics Inc. and AstraZeneca Plc at a big conference foreshadowed an increasingly competitive landscape for weight-loss therapies, sending down shares of ...

Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most of those gains flowing to Eli Lilly and Novo Nordisk, the dominant players ...

We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...

Viking Therapeutics' weight loss drug VK2735 may challenge Novo Nordisk and Eli Lilly's dominance in the obesity drug space ...

These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates appetite and digestion. The medications control blood sugar and help people ...

Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...

We reveal the 3 investment megatrends that are captured in the top 10 holdings of the Vanguard MSCI Index International Shares ETF (ASX: VGS).

After a protracted rough patch—which has included layoffs, partnership terminations and lawsuits—San Francisco’s Nektar ...

Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing better-than-expected results from a Phase 1 trial. The news sent the stock sharply ...

Viking Therapeutics reported an 8.2% weight loss with VK2735, but a sell-off followed. Read why VKTX stock's long-term ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...